• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎的免疫学最新进展及新型治疗策略

Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis.

机构信息

Department of Biology, College of Science, UAE University, Al Ain 15551, United Arab Emirates.

Department of Pathology, University of Würzburg, 97080 Würzburg, Germany.

出版信息

Cells. 2021 Jun 4;10(6):1392. doi: 10.3390/cells10061392.

DOI:10.3390/cells10061392
PMID:34200009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8226506/
Abstract

Atopic dermatitis (AD) is one of the most prevalent inflammatory disease among non-fatal skin diseases, affecting up to one fifth of the population in developed countries. AD is characterized by recurrent pruritic and localized eczema with seasonal fluctuations. AD initializes the phenomenon of atopic march, during which infant AD patients are predisposed to progressive secondary allergies such as allergic rhinitis, asthma, and food allergies. The pathophysiology of AD is complex; onset of the disease is caused by several factors, including strong genetic predisposition, disrupted epidermal barrier, and immune dysregulation. AD was initially characterized by defects in the innate immune system and a vigorous skewed adaptive Th2 response to environmental agents; there are compelling evidences that the disorder involves multiple immune pathways. Symptomatic palliative treatment is the only strategy to manage the disease and restore skin integrity. Researchers are trying to more precisely define the contribution of different AD genotypes and elucidate the role of various immune axes. In this review, we have summarized the current knowledge about the roles of innate and adaptive immune responsive cells in AD. In addition, current and novel treatment strategies for the management of AD are comprehensively described, including some ongoing clinical trials and promising therapeutic agents. This information will provide an asset towards identifying personalized targets for better therapeutic outcomes.

摘要

特应性皮炎(AD)是最常见的非致命性皮肤病之一,在发达国家中,多达五分之一的人口受其影响。AD 的特征是反复发作的瘙痒和局部湿疹,具有季节性波动。AD 引发特应性进行曲现象,在此期间,婴儿 AD 患者易发生渐进性二次过敏,如过敏性鼻炎、哮喘和食物过敏。AD 的病理生理学非常复杂;疾病的发作是由多种因素引起的,包括强烈的遗传易感性、表皮屏障破坏和免疫失调。AD 最初的特征是先天免疫系统缺陷和对环境因子的强烈适应性 Th2 反应偏斜;有强有力的证据表明,这种疾病涉及多个免疫途径。对症缓解治疗是管理疾病和恢复皮肤完整性的唯一策略。研究人员正试图更准确地确定不同 AD 基因型的贡献,并阐明各种免疫轴的作用。在这篇综述中,我们总结了先天和适应性免疫反应细胞在 AD 中的作用的最新知识。此外,还全面描述了 AD 的当前和新型治疗策略,包括一些正在进行的临床试验和有前途的治疗药物。这些信息将有助于确定个性化的治疗靶点,以获得更好的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1901/8226506/05ace0de6fce/cells-10-01392-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1901/8226506/fe83fbc63643/cells-10-01392-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1901/8226506/05ace0de6fce/cells-10-01392-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1901/8226506/fe83fbc63643/cells-10-01392-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1901/8226506/05ace0de6fce/cells-10-01392-g002.jpg

相似文献

1
Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis.特应性皮炎的免疫学最新进展及新型治疗策略
Cells. 2021 Jun 4;10(6):1392. doi: 10.3390/cells10061392.
2
Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation.特应性皮炎的上皮屏障功能障碍:一个连接微生物组改变和免疫失调的皮肤-肠道-肺模型。
Br J Dermatol. 2018 Sep;179(3):570-581. doi: 10.1111/bjd.16734. Epub 2018 Jul 11.
3
The atopic march and atopic multimorbidity: Many trajectories, many pathways.特应性进程和特应性多种共病:多种轨迹,多种途径。
J Allergy Clin Immunol. 2019 Jan;143(1):46-55. doi: 10.1016/j.jaci.2018.11.006. Epub 2018 Nov 17.
4
Atopic dermatitis: the skin barrier and beyond.特应性皮炎:皮肤屏障及其他。
Br J Dermatol. 2019 Mar;180(3):464-474. doi: 10.1111/bjd.16934. Epub 2018 Oct 10.
5
Patterns of allergic sensitization and atopic dermatitis from 1 to 3 years: Effects on allergic diseases.1 至 3 岁时的过敏致敏和特应性皮炎模式:对过敏性疾病的影响。
Clin Exp Allergy. 2018 Jan;48(1):48-59. doi: 10.1111/cea.13063. Epub 2017 Dec 15.
6
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation.特应性皮炎:一种皮肤屏障改变和免疫失调的疾病。
Immunol Rev. 2011 Jul;242(1):233-46. doi: 10.1111/j.1600-065X.2011.01027.x.
7
Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights.特应性皮炎:基于新病理生理学见解而不断演变的治疗理念。
J Allergy Clin Immunol. 2008 Dec;122(6):1074-81. doi: 10.1016/j.jaci.2008.09.042. Epub 2008 Nov 6.
8
Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity.自发性特应性皮炎由先天性免疫介导,而特应性进程中的继发性肺部炎症则需要适应性免疫。
J Allergy Clin Immunol. 2016 Feb;137(2):482-91. doi: 10.1016/j.jaci.2015.06.045. Epub 2015 Aug 20.
9
Relationship of skin barrier breakdown and eosinophilic esophagitis.皮肤屏障破坏与嗜酸性食管炎的关系。
J Allergy Clin Immunol. 2020 Jan;145(1):90-92.e1. doi: 10.1016/j.jaci.2019.11.005. Epub 2019 Nov 15.
10
The ins and outs of an 'outside-in' view of allergies: atopic dermatitis and allergy prevention.过敏的“由外而内”观点面面观:特应性皮炎与过敏预防。
Curr Opin Pediatr. 2018 Aug;30(4):576-581. doi: 10.1097/MOP.0000000000000646.

引用本文的文献

1
Human YKL-40 antibody alleviates atopic dermatitis-like skin inflammation by inhibiting exosome secretion via the JAK3/STAT6 pathway.人YKL-40抗体通过JAK3/STAT6途径抑制外泌体分泌,从而减轻特应性皮炎样皮肤炎症。
Arch Pharm Res. 2025 Sep 9. doi: 10.1007/s12272-025-01564-y.
2
Unlocking the molecular pathway of atopic dermatitis: journey so far and roads ahead.揭示特应性皮炎的分子途径:迄今为止的历程与未来之路。
Inflammopharmacology. 2025 Aug 18. doi: 10.1007/s10787-025-01900-0.
3
Symbiotic bacteria-mediated imbalance and repair of immune homeostasis: exploring novel mechanisms of microbiome-host interactions in atopic dermatitis.

本文引用的文献

1
Molecular Mechanisms of Atopic Dermatitis Pathogenesis.特应性皮炎发病机制的分子机制。
Int J Mol Sci. 2021 Apr 16;22(8):4130. doi: 10.3390/ijms22084130.
2
Autoreactive T cells and their role in atopic dermatitis.自身反应性 T 细胞及其在特应性皮炎中的作用。
J Autoimmun. 2021 Jun;120:102634. doi: 10.1016/j.jaut.2021.102634. Epub 2021 Apr 20.
3
Human cutaneous B cells: what do we really know?人类皮肤B细胞:我们究竟了解多少?
共生细菌介导的免疫稳态失衡与修复:探索特应性皮炎中微生物群 - 宿主相互作用的新机制
Front Immunol. 2025 Jul 23;16:1649857. doi: 10.3389/fimmu.2025.1649857. eCollection 2025.
4
A novel anti-OX40 human monoclonal antibody that blocks OX40/OX40L signaling and depletes OX40 T cells.一种新型抗OX40人单克隆抗体,可阻断OX40/OX40L信号传导并消耗OX40 T细胞。
Mar Life Sci Technol. 2025 Apr 7;7(2):328-339. doi: 10.1007/s42995-025-00284-y. eCollection 2025 May.
5
Anti-Inflammatory Activity of L. Extract in 2,4-Dinitrochlorobenzene-Induced Dermatitis in Rats.L提取物对2,4-二硝基氯苯诱导的大鼠皮炎的抗炎活性。
Pharmaceuticals (Basel). 2025 Mar 5;18(3):370. doi: 10.3390/ph18030370.
6
Saccharomyces boulardii (CNCM I-745) ameliorates Ovalbumin-induced atopic dermatitis by modulating the NF-κB signaling in skin and colon.布拉氏酵母菌(CNCM I-745)通过调节皮肤和结肠中的NF-κB信号通路改善卵清蛋白诱导的特应性皮炎。
Arch Dermatol Res. 2025 Feb 26;317(1):500. doi: 10.1007/s00403-025-04057-6.
7
Atopic Dermatitis Immune Dysregulation as Dengue Predisposing Factor.特应性皮炎免疫失调作为登革热的易感因素。
J Inflamm Res. 2024 Nov 27;17:9875-9887. doi: 10.2147/JIR.S493946. eCollection 2024.
8
Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts.新兴的抗炎性 COPD 治疗方法:潜在的心血管影响。
Int J Chron Obstruct Pulmon Dis. 2024 Nov 21;19:2481-2495. doi: 10.2147/COPD.S498255. eCollection 2024.
9
Causal relationship and mediation effects of immune cells and plasma metabolites in atopic dermatitis: A Mendelian randomization study.特应性皮炎中免疫细胞和血浆代谢物的因果关系和中介效应:一项孟德尔随机化研究。
Medicine (Baltimore). 2024 Oct 11;103(41):e39932. doi: 10.1097/MD.0000000000039932.
10
Treatment of Atopic Dermatitis in Children.儿童特应性皮炎的治疗
Cureus. 2024 Sep 14;16(9):e69416. doi: 10.7759/cureus.69416. eCollection 2024 Sep.
Ann Transl Med. 2021 Mar;9(5):440. doi: 10.21037/atm-20-5185.
4
Atopic Dermatitis.特应性皮炎
N Engl J Med. 2021 Mar 25;384(12):1136-1143. doi: 10.1056/NEJMra2023911.
5
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.用于治疗特应性皮炎的生物制剂:现状与未来展望
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1053-1065. doi: 10.1016/j.jaip.2020.11.034.
6
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.Janus 激酶抑制剂治疗特应性皮炎:一种有前景的治疗方式。
Clin Exp Dermatol. 2021 Jul;46(5):820-824. doi: 10.1111/ced.14567. Epub 2021 Feb 28.
7
miR103a-3p in extracellular vesicles from FcεRI-aggregated human mast cells enhances IL-5 production by group 2 innate lymphoid cells.FcεRI 聚集的人肥大细胞来源的细胞外囊泡中的 miR103a-3p 增强了 2 型固有淋巴细胞的 IL-5 产生。
J Allergy Clin Immunol. 2021 May;147(5):1878-1891. doi: 10.1016/j.jaci.2021.01.002. Epub 2021 Jan 17.
8
Intricate Relationship Between Adaptive and Innate Immune System in Allergic Contact Dermatitis.变应性接触性皮炎中适应性免疫系统和固有免疫系统的复杂关系。
Yale J Biol Med. 2020 Dec 29;93(5):699-709. eCollection 2020 Dec.
9
JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.JAK1/2 抑制作用可损害特应性皮炎中炎症性树突状表皮细胞的发育和功能。
J Allergy Clin Immunol. 2021 Jun;147(6):2202-2212.e8. doi: 10.1016/j.jaci.2020.11.041. Epub 2020 Dec 15.
10
Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial.神经激肽-1受体拮抗剂曲帕坦对特应性皮炎瘙痒有混合作用:随机临床试验EPIONE的结果
J Eur Acad Dermatol Venereol. 2021 May;35(5):e338-e340. doi: 10.1111/jdv.17090. Epub 2021 Jan 7.